Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC
Status:
Withdrawn
Trial end date:
2018-02-28
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine how 2 doses mirvetuximab soravtansine affects
the amount and activity of folate receptor alpha proteins in tumor cells of patients who have
completed standard neoadjuvant treatment and are scheduled to have their tumors surgically
removed.